# Schall, Brown & Schwartz Investigates iRhythm Over Q3 Revenue Miss and Zio MCT Delay

> Schall, Brown & Schwartz is investigating iRhythm Holdings for securities law violations after Q3 revenue missed consensus and shares fell 33.7%.

- Published: 2026-11-22T18:03:53+00:00
- Section: Legal & Disputes
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-22/irhythm-sbs-securities-investigation
- Source: [Business Wire](https://www.businesswire.com/news/home/20261122044597/en/)

## Key takeaways

- Schall, Brown & Schwartz LLP is investigating iRhythm Holdings for potential securities law violations.
- iRhythm reported Q3 2026 revenue below consensus estimates on November 5, 2026.
- iRhythm said it does not expect to submit Zio MCT to the FDA this year, and shares fell 33.7% the next day.

Schall, Brown & Schwartz LLP is investigating iRhythm Holdings, Inc. for potential violations of the securities laws, the firm said in a [Business Wire](https://www.businesswire.com/news/home/20261122044597/en/) announcement on November 22, 2026. The investigation concerns whether iRhythm issued false or misleading statements or failed to disclose information pertinent to investors.

## What Prompted the iRhythm Investigation

iRhythm reported its third-quarter financial results on November 5, 2026, with revenue below consensus estimates for the quarter. The company also said it does not expect to submit Zio MCT to the FDA this year. Shares of iRhythm fell 33.7% the next day.

Schall, Brown & Schwartz is a national shareholder rights litigation firm. The firm said it is investigating claims on behalf of iRhythm investors and invited shareholders who suffered a loss to contact Brian Schall or David Schwartz to discuss their rights free of charge.

The same firm announced an investigation into Advanced Micro Devices on November 20, 2026, [The future of trading](https://capital.com/en-int/news/amd-investors-have-opportunity-to-join-advanced-micro-devices-inc) reported, citing a Hunterbrook report that alleges AMD issued false statements and bills over 20% of revenue to China and Hong Kong. AMD shares fell more than 7.7% the same day.

[iRhythm Technologies](https://akta.pro/company-profiles/0000jpx/irhythm-technologies) is a San Francisco-based cardiac monitoring company founded in 2006, according to akta.pro [company records](https://akta.pro/company-data). Its Zio platform provides ambulatory electrocardiogram monitoring, and the company has between 1,001 and 5,000 employees.

## iRhythm's Zio MCT Filing and Revenue Guidance

According to the same records, iRhythm has targeted its next-generation Zio MCT device for FDA approval and a first-half 2027 launch, a major refresh of the Zio AT product line. The company's full-year 2026 revenue guidance stands at $875 million to $885 million, representing 17-18% annual growth. Full-year 2025 revenue was $747.1 million, up 26.2% year over year.

## Earlier iRhythm Securities Inquiries

Kirby McInerney LLP said on November 13, 2026 that it was investigating potential securities law violations by iRhythm, prompted by the company's third-quarter 2026 results, FinancialContent Business Page reported. The summary cited revenue of $221.6 million missing consensus and the Zio MCT FDA filing moving to 2027, with shares falling 30.7%.

Bronstein, Gewirtz & Grossman, LLC said on October 18, 2026 that it was investigating potential claims on behalf of iRhythm stockholders who purchased securities before January 11, 2022, The future of trading reported.

## Zio MCT Approval Timeline

iRhythm plans to file for FDA approval of Zio MCT in 2027, Seeking Alpha reported on November 6, 2026, while raising its 2026 revenue outlook to $890 million to $895 million.

## Companies in this story

- [iRhythm Technologies company profile](https://akta.pro/company-profiles/0000jpx/irhythm-technologies) · website: http://www.irhythmtech.com

---
News for Agent · https://newsforagent.com/llms.txt
